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Volume 54, Number 2 Cambria et al 543Unstable symptomatic carotid plaques are associated with
an increased incidence of new ipsilateral silent embolic
events after CAS compared with CEA.18-20 In the absence
of data showing comparable risks of stroke and silent em-
boli for CAS, angioplasty and stenting should only be
offered to symptomatic patients when mitigating factors
suggest an unacceptable risk with CEA.
It is likely that CAS will continue to improve with (1)
better patient selection, (2) better embolic protection de-
vices, (3) better stents (membrane or mesh covered), (4)
technical improvements (eg, avoiding aortic arch manipu-
lations), and (5) additional operator experience.19 Adop-
tion of all these may well improve CAS outcomes and make
it a fair alternative to CEA, at least in certain patient
subgroups. However, the current evidence indicates that
we are not there yet, and it seems unfair to spin either
CREST2 or the AHA/ASA guidelines1 to conclude that we
are.
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Richard P. Cambria, MD, Robert Zwolak, MD, and Peter Gloviczki, MD, Boston, Mass; Lebanon, NH;
and Rochester, Minn
Is carotid artery stenting (CAS) a fair alternative to carotid
endarterectomy (CEA) for symptomatic carotid stenosis? In theoore review the available evidence and conclude the answer is
no” regardless of the context of the recently published American
eart Association/American Stroke Association (AHA/ASA)
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August 2011544 Cambria et alguidelines in which CAS is described as an “alternative” in symp-
tomatic patients.1 Since the Society for Vascular Surgery (SVS) is
one of a consortium of medical professional organizations who
have endorsed these guidelines, it is appropriate for our society to
comment. As a professional society, the SVS has responded to the
question posed in this article in a variety of formats and commu-
nications over a number of years in a manner similar to Paraskevas
et al, with a firm “no.” How is it, then, that the SVS would
co-sponsor the AHA/ASA guidelines? Indeed, how could it be
that two of the communication authors provide de-facto endorse-
ment of the guidelines by serving as co-authors? The AHA/ASA
document is a high quality article that addresses the entire spec-
trum of extracranial cerebrovascular issues very well. CAS for
symptomatic carotid disease is an alternative for CEA only in rare
clinical situations, given the current state of CAS technology and
the available clinical evidence documenting CEA as having signif-
icantly lower stroke/death rates when compared to CAS.2
The SVS clinical practice guidelines referable to carotid dis-
ease, originally published in 2008 and currently undergoing up-
date, indicate that CEA plus optimal medical therapy is the pre-
ferred treatment for most patients with symptomatic carotid
stenosis. Using the identical “GRADE” system applied in the
AHA/ASA guidelines, the SVS reported CEA as a class I recom-
mendation supported by high-quality evidence.3 The SVS guide-
lines further state (weak recommendation plus low quality evi-
dence) that “carotid stenting is a potential alternative treatment to
CEA in symptomatic patients with 50% stenosis and high peri-
operative risk.”3 A careful reading of the AHA/ASA guidelines, in
fact, reveals that its recommendations for revascularization are
entirely consistent with the 2008 SVS clinical practice guidelines,
despite the addition of CREST and other recent randomized trials
as summarized in Table 1 of the communication by Paraskevas et
al. The AHA/ASA guidelines indicate (Class I recommendation)
that CEA is the treatment for symptomatic carotid stenosis, and
that “CAS is indicated as an alternative to CEA for symptomatic
patients at average or low risk of complications associated with
endovascular intervention . . . ” The recommended threshold for
acceptable stroke/death complications was quoted at 6% for both
procedures, a figure that was originally promulgated by consensus
for CEA (only), published in 1995 as part of an AHA consensus
guideline and not updated in a scientific manner since then, to our
knowledge.4 We now know, in fact, that this 6% threshold rather
accurately states the stroke/death risk of CAS in symptomatic
patients (in the hands of experts); multiple current studies indicate
that the corresponding figure for CEA is in the 3% range.2,5 The
long awaited CREST data indicate periprocedural stroke/death
risk for CAS in symptomatic patients is essentially two-fold that for
CEA.2 Indeed, the composite end point (ie, stroke/death/MI) of
CREST notwithstanding, the editorial accompanying the initial
publication of CREST succinctly stated a perspective on all the
available randomized, controlled trials, with the observation
“. . . the results (of CREST) are broadly consistent with those in
previous trials. Namely CAS is associated with a higher periproce-
durial risk of stroke or death (compared to CEA), a difference that
was still significant at 4 years.”6 Clearly, this difference is most
dramatic in symptomatic patients. The European randomized trials
of CAS vs CEA have been criticized frequently for poor training
and modest experience of the CAS operators with the implication
that CAS results would have been better had more skilled inter-
ventionalists been at the controls. Preferring to interpret the Eu-
ropean evidence without bias toward interventionalist skill, Roth-
well called for a moratorium on CAS in symptomatic patients.7
Strict performance criteria were employed from the outset for CAS
operators in CREST, with results demonstrating a 30-day stroke/
death rate of 6.0  0.9% for CAS, while the analogous value was
7.4% in the European ICSS; the difference in these complication
rates is not significantly different between the two trials.2,5,8
The SVS has stated its position, doubtlessly consistent with the
vast majority of not only vascular surgeons, but all clinicians who
aspire to practice evidence-based medicine, that CEA is the treat-ent of choice for symptomatic carotid stenosis for the vast
ajority of patients. Is then, the SVS endorsement of the recently
ublished AHA/ASA guidelines referable to extracranial cerebro-
ascular disease somehow in conflict with that position? We think
ot, and it is appropriate to review the history of this document,
he prominent role the SVS designated members of the writing
ommittee imparted (including two authors of the accompanying
ommunication), and the final considerations of both the SVS
ocument Oversight and Executive committees in ultimately
greeing to endorse the guidelines. The document itself (all 78
rinted pages of text and 750 references) is an admirable compen-
ium of information on all issues referable to extracranial cerebro-
ascular disease, and the consortium of professional societies as
ndorsing signators is indeed impressive. This is not to say that the
VS was swayed by a “go with the majority” mentality. In the
ormation of this writing group, perhaps as a function of the AHA
uidelines process, vascular surgery was initially afforded but one
osition on the writing committee, and the SVS declined the
nvitation to participate. Extensive negotiations between the SVS
nd the AHA/ACCF guidelines group ultimately produced a
ore appropriate representation of vascular surgeon authors on
he writing group, and thereafter the SVS agreed to participate.
uch consensus guidelines involve debate and compromise, and
ur vascular surgeon representatives were often in a position of
holding the line” against enthusiasm for CAS from some quarters,
egardless of the evidence supporting CEA in symptomatic pa-
ients. Careful review of the AHA/ASA guidelines by the SVS
ocument Oversight Committee indeed cited use of the term
alternative” in characterization of CAS. The SVS Executive Com-
ittee carefully reviewed the guidelines and in conference with the
uidelines principle authors (Drs Thomas G. Brott and Jonathan
. Halperin), clarified that the revascularization recommendation
ection does, indeed, indicate that CEA is the preferred treatment
or symptomatic carotid stenosis. The consideration of CAS as an
alternative” therapy was not intended to imply “equivalence”
ccording to these authors. Debate about alternative language to
he term “alternative” was considered counterproductive as AHA
rocess would have mandated return of the document to all 16
ponsoring societies and all authors to alter a single word. It is
orth emphasizing that the AHA/ASA guidelines indicate CEA is
he treatment of choice in appropriately selected asymptomatic
atients (Class II A recommendation, evidence level A) and that
AS “might be considered in highly selected patients with asymp-
omatic stenosis . . . but its effectiveness compared to medical
herapy alone is not well established” (Class II B recommendation,
vidence level B). Again, such recommendations are entirely con-
istent with the 2008 SVS Clinical Practice Guidelines.
The SVS, in its prior position statements and guidelines and
gain in this forum, unequivocally states that CEA is the treatment
f choice for patients with symptomatic carotid stenosis who are at
cceptable risk for surgery. The SVS endorsed the AHA/ASA
uidelines document after careful consideration, in deference and
ith thanks to its vascular surgeon co-authors, Drs Ruth L. Bush,
esley S. Moore and Thomas S. Riles. It is anticipated that “alter-
ative” will be considered “equivalent” in some quarters, regardless of
he preponderance of evidence in support of CEA for patients
ith symptomatic carotid stenosis. Perhaps this reflects human nature
r the imperfect nature of consensus documents. The soon-to-be-
ublished SVS updated and revised Clinical Practice Guidelines refer-
ble to carotid disease will offer a focused perspective for clinicians
ncorporating all current data. In summary, we agree with the authors
f the accompanying communication that (1) CAS outcomes are
ikely to improve over time, and (2) that current evidence indicates
troke and death rates are significantly lower for CEA vs CAS in
ymptomatic patients.
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